Beta cells in the pancreas respond better to blood glucose changes, reducing insulin resistance commonly associated with excess weight
Track which foods and beverages worsen or improve your symptoms
Securities and Exchange Commission
For patients with celiac disease and type 2 diabetes who struggle with glycemic control or weight management despite lifestyle modifications, pharmacological interventions like tirzepatide may offer significant benefits
TB-4: Clinical Data for Unrelated Endpoints Meaningful human trial data for full-length TB-4 (corneal-healing Phase 2/3 as RGN-259, plus cardiac and wound-repair programs) Clean Phase 1 safety Cosmetic dosing is extrapolated from these programs Note: Full-length trial data does not transfer to the TB-500 fragment, so verify vial identity
Nausea is the most common side-effect GLP-1 symptom, followed by vomiting, sour burps, heartburn and gastroparesis Side-Effect Profile of GLP-1s, from Worst to Best (% reflects estimated number of patients with GI side-effects) 50% Semaglutide (Ozempic, Rybelsus, Wegovy) 40% Tirzepatide (Saxenda, Mounjaro) 40% Liraglutide (Victoza, Saxenda) 30% Lixisenatide (Adlyxin USA, Lyxumia UK) 10% Dulaglutide (Trulicity) 10% Exenatide (Byetta, Bydureon) Wegovy, Mounjaro, and Saxenda FDA-approved for weight loss